Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1
Authors:
- Carmen BozicCBCarmen Bozic
- Gary BloomgrenGBGary Bloomgren
- 17 August 2011
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 70 (5) , 742-750
Abstract
Objective: A study was undertaken to define the prevalence of anti‐JC virus (JCV) antibodies in multiple sclerosis (MS) patients and to evaluate the analytical false‐negative rate of a 2‐step anti‐JC virus antibody assay.Methods: STRATIFY‐1 is an ongoing, longitudinal, observational study of relapsing MS patients in the United States who are being treated or considering treatment with natalizumab. Baseline serum and plasma samples were collected for anti‐JC virus antibody detection using an analytically validated, 2‐step, virus‐like particle‐based enzyme‐linked immunosorbent assay. Urine was collected for JC virus DNA detection.Results: At baseline (n = 1,096), overall anti‐JC virus antibody prevalence was 56.0% (95% confidence interval [CI], 53.0‐59.0) in STRATIFY‐1 patients, with an assay false‐negative rate of 2.7% (95% CI, 0.9–6.2). Prevalence was significantly lower in females (53.4%; 95% CI, 49.9–56.8) than males (64.3%; 95% CI, 58.2–70.0) and increased with age, p = 0.0019 and p = 0.0001, respectively. Prevalence was similar in patients regardless of natalizumab exposure or prior immunosuppressant use, p = 0.9709 and p = 0.6632, respectively. STRATIFY‐1 results were generally consistent with those observed in another large North American cohort, TYGRIS‐US (n = 1,480).Interpretation: Baseline results from STRATIFY‐1 are consistent with other studies utilizing this assay that demonstrate a 50 to 60% prevalence of anti‐JC virus antibodies, a low false‐negative rate, and an association of increasing age and male gender with increasing anti‐JC virus antibody prevalence. Neither natalizumab exposure nor prior immunosuppressant use appear to affect prevalence. Longitudinal data from STRATIFY‐1 will confirm the stability of anti‐JC virus antibody prevalence over time. ANN NEUROL 2011Keywords
This publication has 21 references indexed in Scilit:
- Anti‐JC virus antibodies: Implications for PML Risk StratificationAnnals of Neurology, 2010
- Assessment of JC virus DNA in blood and urine from natalizumab‐treated patientsAnnals of Neurology, 2010
- Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of AustraliansJournal of General Virology, 2010
- Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory TherapiesAnnual Review of Medicine, 2010
- Characterization of JC human polyomavirus infection in a Portuguese populationJournal of Medical Virology, 2010
- Investigation of pre‐diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus‐infected patientsJournal of Medical Virology, 2009
- Seroepidemiology of Human PolyomavirusesPLOS Pathogens, 2009
- Antibodies to JC and BK viruses among persons with non‐Hodgkin lymphomaInternational Journal of Cancer, 2005
- The Dynamics of Herpesvirus and Polyomavirus Reactivation and Shedding in Healthy Adults: A 14‐Month Longitudinal StudyThe Journal of Infectious Diseases, 2003
- Prevalence of Antibodies in Human Sera against JC Virus, an Isolate from a Case of Progressive Multifocal LeukoencephalopathyThe Journal of Infectious Diseases, 1973